Martin A. Lehr - 22 Oct 2021 Form 4 Insider Report for Context Therapeutics Inc. (CNTX)

Role: Chief Executive Officer, Director
Signature: /s/ Tyler J. Vivian, Attorney-in-Fact
Issuer symbol: CNTX
Transactions as of: 22 Oct 2021
Net transactions value: +$426,135
Form type: 4
Filing time: 25 Oct 2021, 17:30:32 UTC
Previous filing: 19 Oct 2021
Next filing: 20 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNTX	Common Stock	Purchase	$50,000	+10,000	+11%	$5.00	99,583	22 Oct 2021	Direct
transaction	CNTX	Common Stock	Exercise of out-of-the-money derivative security	$376,135	+52,680		$7.14^*	52,680	22 Oct 2021	Martin Lehr 2000 Trust
transaction	CNTX	Common Stock	Conversion of derivative security		+210,722	+400%		263,402	22 Oct 2021	Martin Lehr 2000 Trust	F1
transaction	CNTX	Common Stock	Conversion of derivative security		+586,476	+223%		849,878	22 Oct 2021	Martin Lehr 2000 Trust	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNTX	Warrant (right to buy)	Exercise of out-of-the-money derivative security	$0	+52,680		$0.000000^*	0	22 Oct 2021	Common Stock	52,680	$7.14	Martin Lehr 2000 Trust
transaction	CNTX	Series A Preferred Stock	Conversion of derivative security		-210,722	-100%		0	22 Oct 2021	Common Stock	210,722		Martin Lehr 2000 Trust	F1, F2
transaction	CNTX	Series Seed Preferred Stock	Conversion of derivative security		-586,476	-100%		0	22 Oct 2021	Common Stock	586,476		Martin Lehr 2000 Trust	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
F2	Fully vested.
F3	Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.